Zetagen is committed to the treatment of craniomaxillofacial bone cancers through our breakthrough technologies. These discoveries, like ZetaDent™, have ancillary benefits to other oral procedures such as the 500,000 dental implants procedures completed annually.
While cancer of the oral cavity is not a common occurrence, approximately 3,500 cases are diagnosed annually. Zetagen has products in development which may have a positive impact for these patients in the near future.
